Simulation of sirolimus exposures and population variability immediately post renal transplantation: Importance of the patient's CYP3A5 genotype in tailoring treatment

Biopharmaceutics and Drug Disposition

Volumn 31, Issue 2-3, 2010, Pages 129-137

  Lukas, John C ^a   Calvo, Rosario ^b   Zografidis, Anastasios ^b   Ortega, Ignacio ^b   Suárez, Elena ^b  

^a PHARSIGHT CORPORATION   (United States)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

CYP3A5 genotype; Dose titration; Renal transplantation; Simulation; Sirolimus

Indexed keywords

CORTICOSTEROID; CYTOCHROME P450 3A5; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG METABOLISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONTE CARLO METHOD;

ADULT; CYTOCHROME P-450 CYP3A; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; POPULATION GROUPS; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 77951047261     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.697     Document Type: Article

References (18)

1. Groth C, Bäckman L, Morales JM, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantion 1999; 67: 1036-1042. (Pubitemid 29200856)
2. Mahalati K, Kahan BD. Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40: 573-585.
3. Stenton SB, Partovi N, Ensom MH. Sirolimus. The evidence for clinical pharmacokinetic monitoring. Clin Pharmacokinet 2005; 44: 769-786.
4. Ferron GM, Mishina EV, Zimmerman JJ, Jusko WJ. Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther 1997; 61: 416-428. (Pubitemid 27195944)
5. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokinetic/pharmacogenetic analysis transplant recipients. Clin Pharmacokinet 2006; 45: 1135-1148. (Pubitemid 43946845)
6. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006; 80: 51-60. (Pubitemid 43946845)
7. Zimmerman JJ. Exposure-response relationships and drug interactions of sirolimus. AAPS J 2004; 6: e28.
8. Holford NH. Target concentration intervention: beyond Y2K. Br J Clin Pharmacol 1999; 48: 9-13.
9. Lukas JC, Samiotaki M, Kontou M, et al. The cytochrome P450 3AP1 genotype shows correlation with clearance (CL/F) in a renal transplant population. http://www.mindcull.com/preview/ESOT-2005.php, ESOT, 2005.
10. Anglicheau D, Le Corre D, Lechaton S, et al. Consequences of genetic polymorphism for sirolimus requirements after renal transplant in patients on primary sirolimus therapy. Am J Transplant 2005; 5: 595-603. (Pubitemid 40313352)
11. Jonge H, Kuypers D. Pharmacogenetics in solid organ transplantation: current status and future directions. Transplant Rev 2008; 22: 6-20. (Pubitemid 350131580)
12. Beal SL, Sheiner LB (eds). NONMEM User's Guides. NONMEM Project Group, University of California at San Francisco: San Francisco, CA; 1992.
13. Wu MJ, Shu KH, Lian JD, Yang CR, Cheng CH, Chen CH. Impact of variability of sirolimus trough level on chronic allograft nephropathy. Transplant Proc 2008; 40: 2202-2205.
14. MacDonald A, Scarola J, Burke JT, Zimmerman JJ. Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 2000; 22(Suppl B): B101-B121. (Pubitemid 30306050)
15. Dansirikul C, Morris RG, Tett SE, Duffull SB. A Bayesian approach for population pharmacokinetic modeling sirolimus. Br J Clin Pharmacol 62: 420-434.
16. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883-892. (Pubitemid 46682728)
17. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785. (Pubitemid 39434437)
18. Flechner SM, Goldfarb D, Modlin C, et al. Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076. (Pubitemid 35216097)